BioCryst PharmaceuticalsvsJohnson & Johnson

BCRX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

BCRX

BioCryst Pharmaceuticals, Inc.

$7.32

Value $1.8B

+0.27%
BCRX's page

BioCryst Pharmaceuticals (BCRX) has a market value of $1.8B and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, BCRX moved +4.6% and JNJ +36.6%. Dividend yield: BCRX none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BCRX$1.8B

    JNJ$644B

    JNJ is 351 times BCRX

  • Revenue, 12 months

    BCRX$962M

    JNJ$99.3B

    JNJ is 103 times BCRX

  • Net income, 12 months

    BCRX-$360M

    JNJ$16.1B

  • Operating margin

    BCRX-30.1%

    JNJ–

  • ROIC

    BCRX–

    JNJ12.4%

  • P/E

    BCRX–

    JNJ40.0

  • Dividend yield

    BCRX0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    BCRX-37.7%

    JNJ+89.1%

    126.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BCRX-37.7%

JNJ+89.1%

5010015020020222023202420252026
Returns by period
PeriodBCRXWith dividendsJNJWith dividends
1 year since November 18, 2025+4.6%Price +4.6%+36.6%Price +33.6%
3 years since November 17, 2023+36.8%+11.0% a yearPrice +36.8%+94.2%+24.8% a yearPrice +78.3%
5 years since November 18, 2021-37.7%-9.0% a yearPrice -37.7%+89.1%+13.6% a yearPrice +64.5%
10 years since November 21, 2016+21.0%+1.9% a yearPrice +21.0%+202.7%+11.7% a yearPrice +132.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BCRXBioCryst PharmaceuticalsJNJJohnson & Johnson

Valuation

BCRXJNJ
Valuation
Price$7.32$267.14
Market value$1.8B$644B
Enterprise value (EV)–$671B
P/E–40.0
P/E, 5-year median–21.9
P/B–7.9
EV/EBIT–37.8
Free cash flow yield19.9%3.2%

Results and growth

BCRXJNJ
Results and growth
Revenue, 12 months$962M$99.3B
Net income, 12 months-$360M$16.1B
Free cash flow, 12 months$366M$20.6B
Earnings per share, 12 months-$1.41$6.59
Revenue growth, year on year94.1%6.1%
Revenue growth a year, past+117.9%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

BCRXJNJ
Margins and returns on capital
Gross margin97.9%67.6%
Operating margin-30.1%–
Net margin-37.4%16.2%
ROIC–12.4%
ROE–19.7%

Balance sheet

BCRXJNJ
Balance sheet
Cash$375M$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover-3.8×18.0×

Dividends and buybacks

BCRXJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BCRX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, BioCryst Pharmaceuticals or Johnson & Johnson?

By market value, Johnson & Johnson ($644B) is about 350.7 times BioCryst Pharmaceuticals ($1.8B), at today's prices.

How did BCRX and JNJ stock do over the last 10 years?

Since November 21, 2016, BCRX's price moved +21.0% and JNJ's +132.3%. With dividends: BCRX +21.0% (+1.9% a year), JNJ +202.7% (+11.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, BCRX or JNJ?

The dividend yield at today's price is none for BioCryst Pharmaceuticals and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, BioCryst Pharmaceuticals or Johnson & Johnson?

Over the last twelve months, the net margin was -37.4% for BioCryst Pharmaceuticals and 16.2% for Johnson & Johnson, and the operating margin -30.1% and –. Revenue was $962M and $99.3B.

Which is the better investment, BioCryst Pharmaceuticals or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.